Acclinate-logo
Talk to Our Team

Clinical trials are critical for evaluating the safety and effectiveness of medical devices and pharmaceutical products. The results of trials guide treatment plans, empowering patients and their care teams to make informed decisions about how to manage an acute illness or chronic condition and improve quality of life.

Unfortunately, clinical trial diversity is a longstanding problem in healthcare and life sciences. Communities of color are historically underrepresented in trials. That means researchers – and physicians – don’t know as much about how approved treatments work for these populations as they do for white Americans.  

A more inclusive clinical trial process is vital for advancing medical knowledge and helping the healthcare industry rebuild trust with communities of color. Here’s what today’s researchers need to know about addressing diversity in healthcare and the importance of representation in clinical trials.

The Importance of Diversity in Clinical Trials

The National Institute on Minority Health and Health Disparities (NIMHD) notes several benefits of clinical trials. These include determining whether a new intervention is safer or more effective than existing treatments, exploring how to detect diseases earlier, and studying how to improve the quality of life in patients with chronic conditions or acute illnesses. Medical research and advances in healthcare depend on the clinical trial process.

Clinical trials benefit from a diverse population of participants because no two people experience a disease the same way. Differences in biology and genetics may exist among people that can impact how a drug works and how they respond to treatment. (This explains why there seems to be one person in every household who bounces back from the flu faster than everyone else.)  

NIMHD pointed out that many factors can influence whether someone develops a disease, as well as how someone responds to a treatment. These include but aren’t limited to age, biological sex, genetic variations, environmental conditions, or additional diseases.

The results of a clinical trial reflect the population that participated in the trial. As Harvard Medical School puts it, “If [trials] only include participants from a narrow demographic group, the results may not accurately represent the broader population.” This may result in treatments that are less effective – or even harmful – to certain segments of the population.  

Clinical Trial Diversity: Healthcare and Medical Research Implications

Historically, communities of color have been underrepresented in the clinical trial process. According to the U.S. Food and Drug Administration (FDA), only 11% of participants in new drug trials in 2020 were Hispanic, and only 8% of participants were Black, despite these communities of color making up 19% and 14% of the U.S. population, respectively. In contrast, white Americans make up 60% of the population but 75% of clinical trial participants.

Looking at data from individual trials, representation only gets worse. In a 2022 Lancet study, 10% of clinical trials reported enrollment that was 100% White – while 21% of trials had no Black enrollees and 25% had no Hispanic participants. Similarly, a 2022 Journal of the American Medical Association paper found Americans over the age of 75 are underrepresented in clinical trials relative to their age and disease burden.  

This lack of clinical trial diversity poses a problem for many reasons. First, if a clinical trial has no participants from communities of color, then researchers simply don’t know how a treatment will affect those communities. In fact, a 2022 Health Affairs paper concluded that less than 20% of drug trials reported data on specific treatment benefits or side effects for Black patients.

Another issue, a second Lancet paper noted, is that over-representation of white participants is a “stark contrast” to the disease burden in communities of color. Data from the Centers for Disease Control and Prevention (CDC) indicated communities of color have a higher prevalence of obesity and diabetes than white Americans. Additionally, members of communities of color are more likely to receive a late-stage cancer diagnosis, according to the Kaiser Family Foundation. This matters because late-stage cancer generally is more difficult and expensive to treat and has a higher mortality rate than early-stage cancer.

Diversity in Healthcare and the Importance of Representation

In 2022, the FDA took additional steps, releasing a new draft guidance to improve clinical trial diversity that provides recommendations on the approach for developing a Race and Ethnicity Diversity Plan. The agency’s guidance stated researchers “should define enrollment goals for underrepresented racial and ethnic participants as early as practicable in clinical development for a given indication,” with an emphasis on differences in safety or effectiveness associated with race or ethnicity. Critically, this draft guidance represents an important shift: It instructs research sponsors to submit diversity plans to the agency prior to the start of pivotal studies.

That said, the imperative to enhance clinical trial enrollment and diversity is more than a regulatory push. A 2023 New England Journal of Medicine perspective offered three important benefits:  

  • Earn and rebuild trust. When patients see results from trials with participants with whom they identify, they are more likely to trust the results of the trial – and potentially benefit from a proven treatment.  
  • Promote fairness. Making it easier for underrepresented populations to participate in clinical trials can “promote fairer distribution of gains in medical knowledge.” This may require steps such as recruiting participants in community-based clinics, limiting the number of required in-person visits, and compensating patients for their time (including travel).
  • Advance knowledge. By improving clinical trial diversity, healthcare stakeholders can better understand two things. One is how disease burdens impact communities of color and other populations traditionally underrepresented in trials. The other is how specific treatments work for these populations – and, if they don’t, what questions should drive further research.

Identifying and recruiting more diverse patient populations for trials benefits researchers, patients, and the medical community.

Boost inclusivity in trials faster and for the long term by zeroing in on the populations you lack. Acclinate gives you access to communities of color, facilitates engagement around your trials, and then analyzes the data generated to predict and plan where and when your next effort should happen to create the ongoing representation you need. To learn more, schedule a 1:1 Meeting.

Recent Posts

doctor using laptop computer
3 Min Read

Though the life sciences industry has committed to improving diversity in clinical trials, there’s still work to be done. Childhood asthma is a case i...

Read More
Unpacking the Latest FDA Guidance: Diversity in Clinical Trials for Pharma
3 Min Read

Earlier this year, the U.S. Food and Drug Administration updated its guidance document on collecting race and ethnicity data in clinical trials. The d...

Read More
Clinical Trial Recruitment Strategies that Increase Diversity
3 Min Read

Under 2022’s Food and Drug Omnibus Reform Act, clinical trial sponsors are required tosubmit diversity action plans with pivotal drug studies such as ...

Read More
Using Clinical Trial Services to Connect with Communities of Color
4 Min Read

Clinical research requires trust between the patient and the pharmaceutical companies. When that trust has been damaged, patients will avoid participa...

Read More
Overcome Clinical Trial Recruitment Challenges: Start with Affective Trust
4 Min Read

Inclusive clinical research populations are necessary for a successful study, and new laws are beginning to mandate diversity action plans to promote ...

Read More
Empowering Healthcare Equity: Celebrating 4 Years of Acclinate's Innovation
1 Min Read

As we celebrate our four-year anniversary, Acclinate stands at the forefront of a crucial revolution in healthcare—empowering communities of color to ...

Read More
Marques Bradley: Coding for a Cause at Acclinate
2 Min Read

When Marques Bradley joined Acclinate amidst the pandemic's uncertainty in October of 2020, it wasn't just another job opportunity; it was a call to m...

Read More
The Consequences of a Lack of Diversity in Clinical Trials
3 Min Read

Your clinical research processes are carefully developed over the years, and the success of your project depends on thoughtful preparation. As pharmac...

Read More
Why Diversity, Equity, and Inclusion in Healthcare Is Vital
4 Min Read

In recent years, organizations in all industries have increased their emphasis on diversity, equity, and inclusion (DE&I). In healthcare, the adde...

Read More
Nurturing Health Equity: A Black History Month Reflection
1 Min Read

As we enter Black History Month, Acclinate proudly reaffirms its commitment to health equity—a mission that is deeply embedded in understanding and ad...

Read More
1 Min Read

‍Birmingham, AL - January 30, 2024 – Acclinate, a trailblazer in advancing health equity through inclusive research, is thrilled to announce its win i...

Read More
Five Ways Pharma Can Support the Importance of Diversity in Healthcare
4 Min Read

In the U.S., Black Americans are three times more likely to die from asthma than whites. There are a number of complex factors that play into this dis...

Read More
Diversity in Healthcare & Clinical Research: Challenges & Opportunities
4 Min Read

Healthcare has a longstanding history of underrepresentation of communities of color. It often begins with the clinical trial process, where longstand...

Read More
Acclinate and Egality Sciences Unite for Health Equity in Hispanic and African American Communities
2 Min Read

In a milestone effort to address the historic underrepresentation of Hispanic and African American communities in clinical research, Acclinate and Ega...

Read More
Unveiling the Path to Inclusivity: DE&I in Clinical Research
1 Min Read

In the dynamic realm of clinical research our commitment to Diversity, Equity, and Inclusion (DE&I) stands as a cornerstone for positive change. A...

Read More
Clinical Trial Diversity: What Does It Really Mean?
3 Min Read

Clinical trials are critical for evaluating the safety and effectiveness of medical devices and pharmaceutical products. The results of trials guide t...

Read More
Acclinate Collaborates with Merck to Increase Clinical Trial Diversity
1 Min Read

Acclinate, an expert in health equity through inclusive research, is collaborating with Merck, known as MSD outside the United States and Canada, to h...

Read More
Clinical Trial Diversity: Unpacking the FDA’s Latest Draft Guidance
3 Min Read

Over the last year and a half, there has been renewed interest from research sponsors to increase diversity in clinical trials. But what is behind thi...

Read More
Celebrating Jasmine Leonard: Acclinate's First NOW Health Equity Award Recipient
2 Min Read

Why NOW? At Acclinate, we believe that the present moment is the most powerful time to drive change. This is why we established the NOW Award, a recog...

Read More
Acclinate partners with Alabama Regional Medical Services
2 Min Read

Acclinate, a leading digital health startup specializing in health equity through inclusive research, is proud to announce a strategic partnership wit...

Read More
Acclinate Hosts Educational Sessions on Artificial Intelligence and Machine Learning (AI/ML)
1 Min Read

BIRMINGHAM, Ala., April 13, 2023 – Acclinate, a digital health company specializing in accessing and engaging communities of color to make better info...

Read More
Acclinate and Savvy Partner to Empower Communities of Color Through Equitable Paid Research Opportunities
2 Min Read

The partnership was formed when the two companies connected on a shared purpose – shaping community experiences through inclusive health opportunities...

Read More
Trialbee and Acclinate to Host Webinar on the 5 Key Trends Poised to Significantly Improve Clinical Trial Patient Diversity in 2023
1 min read

Trialbee and Acllinate will present an informational webinar discussing 5 key trends in diversity for clinical trials in 2023. The webinar aims to pro...

Read More
2 Min Read

CHAPEL HILL, N.C. & BIRMINGHAM, A.L. — Dec. 13, 2022 — Trialbee, the leader in data and technology-based patient recruitment and enrollment for cl...

Read More
NOWINCLUDED Named to Inc.’s 2022 Best in Business List
1 Min Read

Being named to the Inc. 2022 Best in Business list in the Southeast Region category is a major accomplishment for NOWINCLUDED. Recognition of this mag...

Read More
Shayla Wilson joins the Acclinate team
1 Min Read

Acclinate, a leading digital health company, announced today the appointment of Shayla Wilson as Head of Community and Digital Engagement.

Read More
Acclinate selected as an Awardee of Johnson & Johnson's Maternal-fetal Immune Disorders QuickFire Challenge
1 min read

Acclinate has been selected as an awardee in the Maternal-fetal Immune Disorders Quickfire Challenge. The QuickFire Challenges are managed by Johnson ...

Read More
Lightship® and Acclinate Announce Partnership
1 Min Read

Today, we announced our partnership with Lightship®, a leading virtual-first and hybrid provider of clinical research solutions. As partners, we will ...

Read More
Acclinate Wins DPHARM Idol Disrupt 2022
1 min read

DPHARM Idol is an annual competition that recognizes disruptive companies on their technologies and services for their quality, especially for the ben...

Read More
AI/ML: Hero or Villain
3 Min Read

After overhearing a conversation about my company, my 5-year-old niece asked between bites of frosted flakes, “What is A I M L?” I thought about flexi...

Read More
Acclinate's system now patent pending
1 min read

Did you know that Acclinate's system and method of using intelligent AI-based automated determination of clinical trial participation is now patent–pe...

Read More
Clinical Trial Diversity Webinar
1 min read

Achieving sufficient affective trust is necessary for communities of color to feel comfortable participating in clinical research.

Read More
Assessing Pharma's Response to New FDA Guidance on Clinical Trial Diversity
4 Min Read

Today, the U.S. Food and Drug Administration took an important step to increase racial and ethnic diversity in clinical trials by releasing new draft ...

Read More
Camille Pope joins the Acclinate team
1 Min Read

Birmingham, AL ( April 18, 2022) - Acclinate, a leading digital health company, announced the appointment of Camille Pope, PharmD as Chief Medical Lea...

Read More
e-DICT Transforms Clinical Trial Recruitment
2 Min Read

It is common for pharmaceutical companies to carry out thousands of research and clinical trials every year to test new products and drugs. As is the ...

Read More
Healthcare Leaders Join Forces to Transform Digital Clinical Trials Through DEI
1 min read

‍ The Digital Medicine Society (DiMe) announced today a new collaboration with Acclinate, Amgen, GSK, Lightship, Medable, Rubix LS, Sage Bionetworks, ...

Read More
Why Does Minority Participation in Clinical Trials Matter?
3 Min Read

While people of color make up nearly half of the United States population, only a small percentage of them choose to participate in clinical trials – ...

Read More
Time for an industry metric to assess clinical trial diversity
3 Min Read

Racial and ethnic minorities now make up over 42% of the U.S. population. However, the statistics are alarming when we look at corresponding racial an...

Read More
Increased Black Representation
1 Min Read

A medical breach of trust is something that lingers in the minds of Black Americans. From the Tuskegee study to modern mistreatment, the racial landsc...

Read More
Why Black Participation is Important
1 Min Read

Thanks to the endeared Henrietta Lacks, a woman whose cervical cancer cells have majorly contributed to numerous scientific and medical breakthroughs ...

Read More
Why Diversity Initiatives Fail in Clinical Trials
4 Min Read

According to a recent study published in the journal Gastroenterology, Blacks and Hispanics remain noticeably absent from pancreatic cancer clinical t...

Read More
Beacon of hope shines bright on Birmingham
4 Min Read

Dora and I moved to Birmingham in 1993. I was a newly minted Ph.D. from University of Georgia, where I met Dr. Khris McAllister, former Chair of the M...

Read More
Clinical Trials As A Best Treatment Option - Acclinate
2 Min Read

As new trials continue to improve treatment options for patients with all types of cancer, it’s “never too soon to be talking about clinical trials” w...

Read More
Cox Enterprises Social Impact Accelerator Class 2021 - Acclinate
2 Min Read

ATLANTA, Jan. 25, 2021 /PRNewswire/ -- Cox Enterprises has announced the 2021 class of the Cox Enterprises Social Impact Accelerator powered by Techst...

Read More